О Службе крови России
Скажем донору спасибо
Совет служб крови СНГ
Технологический форум
Журналы и статьи
Федеральная программа
Региональные программы
Фирмы предлагают
Хроника событий
Новости РАТ
Вам отвечают специалисты
Наш сайт

The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study

Presenter: Sharon Sha, MD, MS, Clinical Associate Professor, Neurology & Neurological Sciences, Stanford University
Date: Saturday, November 4th, 2017
Time: 3:45 pm Eastern Time
Location: Boston Park Plaza Hotel

The primary objective of the PLASMA study was to evaluate the safety, tolerability and feasibility of repeated infusions of plasma from 18-30 year-old donors in patients with mild to moderate AD. Secondary objectives included evaluating the effect of plasma infusions on multiple clinical assessments, including assessments of functional activity. Nine subjects were enrolled, randomized and treated under the double-blind crossover protocol, and an additional nine subjects were enrolled and treated under an open-label amendment. Results indicate that the plasma infusions were generally well-tolerated, with no treatment-related serious adverse events. The results also demonstrated statistically-significant improvement in clinical assessments of functional activity.

Based on the robust safety profile and signals of efficacy seen in the PLASMA study, Alkahest plans to advance the clinical development of a proprietary next-generation plasma-derived product for the treatment of mild-moderate AD.